-
Holmusk: Using Data to Improve Clinical Outcomes for Cardiovascular Disease in Singapore
en-cphi.cn
April 07, 2017
Holmusk, a global digital health and data analytics company -- has embarked on a three-year partnership with National Heart Centre Singapore (NHCS) to improve care for heart failure and coronary artery disease using big data analytics.
-
DeltaHealth Hospital Shanghai Live Broadcasts Academician Junbo Ge's Coronary Interventions Online
en-cphi.cn
March 30, 2017
Prof. Junbo Ge, China's leading expert in cardiology and an Academician of the Chinese Academy of Sciences, finished two complex coronary intervention procedures at DeltaHealth Hospital·
-
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto?) shows overwhelming efficacy and meets pr
worldpharmanews
February 15, 2017
Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto?) for the prevention of major adverse cardiac events (MACE)...
-
Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study
cphi-online
February 08, 2017
Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint.
-
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underly
worldpharmanews
January 09, 2017
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...
-
FDA to review 3 new diabetes drugs that reduce cardiovascular death risk
europeanpharmaceuticalreview
January 06, 2017
The US Food and Drug Administration (FDA) approved supplemental new drug applications for three type 2 diabetes medicines within the empagliflozin family to include data from the empa-red outcome trial.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
